Literature DB >> 23111142

Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.

Robert W Harrison1, Atul Aggarwal, Fang-shu Ou, Lloyd W Klein, John S Rumsfeld, Matthew T Roe, Tracy Y Wang.   

Abstract

Previous studies describing the no-reflow phenomenon in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) were largely confined to single-center studies or small registries. To better characterize the incidence, predictors, and outcomes of the no-reflow phenomenon in a large contemporary population, we analyzed patients with AMI who were undergoing PCI of native coronary artery stenoses in the CathPCI Registry from January 1, 2004 through September 5, 2008 (n = 291,380). The angiographic no-reflow phenomenon was site reported using a standardized definition. No-reflow developed in 2.3% of the patients with AMI (n = 6,553) during PCI. Older age, ST-segment elevation AMI, prolonged interval from symptom onset to admission, and cardiogenic shock were clinical variables independently associated with the development of no-reflow (p <0.001). The angiographic factors independently associated with no-reflow included longer lesion length, higher risk class C lesions, bifurcation lesions, and impaired preprocedure Thrombolysis In Myocardial Infarction flow (p <0.001). No-reflow was associated with greater in-hospital mortality (12.6% vs 3.8%, adjusted odds ratio 2.20, 95% confidence interval 1.97 to 2.47, p <0.001) and unsuccessful lesion outcome (29.7% vs 6.6%, adjusted odds ratio 4.70, 95% confidence interval 4.28 to 5.17, p <0.001) compared to patients without no-reflow. In conclusion, the development of no-reflow, although relatively uncommon during PCI for AMI, is associated with adverse clinical outcomes. Upfront strategies to reduce the incidence of no-reflow could be considered for high-risk patients to improve outcomes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23111142     DOI: 10.1016/j.amjcard.2012.09.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  60 in total

1.  Olfactory ensheathing cells promote neurite sprouting of injured axons in vitro by direct cellular contact and secretion of soluble factors.

Authors:  R S Chung; A Woodhouse; S Fung; T C Dickson; A K West; J C Vickers; M I Chuah
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

2.  Noninvasive Evaluation of No-Reflow Phenomenon.

Authors:  Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

3.  Multilayer longitudinal strain can help predict the development of no-reflow in patients with acute coronary syndrome without ST elevation.

Authors:  Adem Atıcı; Hasan Ali Barman; Emre Erturk; Omer Faruk Baycan; Serdar Fidan; Koray Celal Demirel; Ramazan Asoglu; Koray Demir; Fatih Ozturk; Ali Elitok; Erugrul Okuyan; Irfan Sahin
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-15       Impact factor: 2.357

4.  Cardiovascular Diagnosis and Therapy (CDT) Editorial: the Minimalist Immediate Mechanical Intervention study.

Authors:  Muhammad Aetesam-Ur-Rahman; Colin Berry
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

5.  The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Alaa Quisi; Gökhan Alıcı
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

6.  Link between aortic valve sclerosis and myocardial no-reflow in ST-segment elevation myocardial infarction.

Authors:  L Korkmaz; H Erkan; M T Ağaç; E Pelit; H Bektas; Z Acar; I Gurbak; F Kara; Ş Çelik
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

7.  Renal Dysfunction on Admission Predicts No-Reflow Phenomenon in Patients Undergoing Manual Thrombus Aspiration during Primary Percutaneous Coronary Intervention.

Authors:  Baris Sensoy; Sezen Baglan Uzunget; SadikKadri Acikgoz; Nur Sensoy; Fatih Sen; Burak Acar; Uğur Canpolat; Ozcan Ozeke; Serkan Cay; Orhan Maden
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

8.  ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.

Authors:  Robert C Hendel; Biykem Bozkurt; Gregg C Fonarow; Jeffrey P Jacobs; Judith H Lichtman; Eric E Smith; James E Tcheng; Tracy Y Wang; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2013-11-15       Impact factor: 24.094

Review 9.  Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.

Authors:  Gagan Kaur; Patrick Baghdasaryan; Balaji Natarajan; Prabhdeep Sethi; Ashis Mukherjee; Padmini Varadarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2021-03-03

10.  Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention.

Authors:  Hala Mahfouz Badran; Ahmed Abdel Fatah; Ghada Soltan
Journal:  J Clin Transl Res       Date:  2020-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.